Sage Rhino Capital’s Takeda Pharmaceutical TAK Stock Holding History

Sage Rhino Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$191K	Sell	11,939 -9	-0.1%	-$149	0.03%	357
2026 Q1	$221K	Buy	11,948 +207	+2%	+$3.63K	0.04%	260
2025 Q4	$183K	Sell	11,741 -970	-8%	-$13.9K	0.03%	291
2025 Q3	$186K	Buy	12,711 +107	+0.8%	+$1.59K	0.04%	276
2025 Q2	$195K	Buy	12,604 +919	+8%	+$13.6K	0.04%	255
2025 Q1	$174K	Sell	11,685 -155	-1%	-$2.17K	0.04%	242
2024 Q4	$157K	Buy	11,840 +1,538	+15%	+$21.1K	0.03%	249
2024 Q3	$146K	Buy	+10,302	New	+$146K	0.03%	256
2024 Q2	–	Sell	-11,787	Closed	-$164K	–	265
2024 Q1	$164K	Buy	+11,787	New	+$171K	0.04%	215
2023 Q4	–	Sell	-11,751	Closed	-$182K	–	247
2023 Q3	$182K	Buy	11,751 +831	+8%	+$12.9K	0.05%	199
2023 Q2	$172K	Buy	10,920 +178	+2%	+$2.92K	0.05%	205
2023 Q1	$177K	Buy	+10,742	New	+$171K	0.05%	203

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Sage Rhino Capital's TAK Position: Q2 2026 in Review

Sage Rhino Capital reduced its Takeda Pharmaceutical (TAK) stake by 0.08% in Q2 2026, selling an estimated $149 and leaving 11,939 shares worth $191K. The position accounts for 0.03% of the portfolio, ranked #357.

Sage Rhino Capital first reported a position in TAK in Q1 2023 and has held it in 12 quarters since. The position peaked at $221K in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Sage Rhino Capital held 11,939 shares of Takeda Pharmaceutical worth $191K as of Q2 2026.
Sage Rhino Capital sold 9 Takeda Pharmaceutical shares in Q2 2026, an estimated $149.
Takeda Pharmaceutical made up 0.03% of Sage Rhino Capital's portfolio in Q2 2026, its #357 holding.
Sage Rhino Capital first reported a position in Takeda Pharmaceutical in Q1 2023 and has held it in 12 quarters since.
Sage Rhino Capital's Takeda Pharmaceutical position peaked at $221K in Q1 2026.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.